GlobalRPH - Lupus News

Medical News

< back to feeds
Lupus News
ImmuPharma PLC: Encouraging Final Phase IIb Results Seen With LUPUZOR™ In Systemic Lupus Erythematosus ImmuPharma PLC (LSE:IMM) the specialist discovery and development pharmaceutical company is pleased to announce the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care. ...more	20 Nov 2009
Saliva Proteins Change As Women Age In a step toward using human saliva to tell whether those stiff joints, memory lapses, and other telltale signs of aging are normal or red flags for disease, scientists are describing how the protein content of women's saliva change with advancing age. The discovery could lead to a simple, noninvasive test for better diagnosing and treating certain age-related diseases in women, they suggest in a report in ACS' Journal of Proteome Research, a monthly publication. ...more	20 Nov 2009
Promise Of A New Lupus Treatment Is A Groundbreaking Achievement Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) today announced positive results from BLISS-76, the second of two large-scale phase III clinical trials of BENLYSTA™ (belimumab) for treating systemic lupus. A full presentation of results from BLISS-52 was recently shared at the 73rd Annual Scientific meeting of the American College of Rheumatology. Both trials succeeded in meeting their primary endpoints, which should make BENLYSTA eligible for approval by the U.S. ...more	04 Nov 2009
Smokers With Common Autoimmune Disorder At Higher Risk For Skin Damage As if there weren't enough reasons to stop smoking, a team of researchers at the Research Institute of the McGill University Health Centre (RI-MUHC) have just found another. A study led by Dr. Christian A Pineau, Co-Director of the Lupus and Vasculitis clinic at the MUHC, has clearly linked skin damage and rashes to smoking in people with systemic lupus erythematosus (SLE). The study was published in a recent issue of the Journal of Rheumatology. ...more	04 Nov 2009
Lupus Research Institute: Benlysta(TM) Trial Results In An Historic Research Breakthrough And Victory For People With Lupus The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - the second positive phase 3 clinical trial of Benlysta (belimumab), the first successfully tested new drug developed specifically for people with systemic lupus. "This is a pivotal moment in lupus research," said Margaret G. ...more	03 Nov 2009
BENLYSTA™ Successful In Second Pivotal Clinical Trial Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) announced positive results from BLISS-76, the second of two large-scale phase III clinical trials of BENLYSTA™ (belimumab) for treating systemic lupus. A full presentation of results from BLISS-52 was recently shared at the 73rd Annual Scientific meeting of the American College of Rheumatology. Both trials succeeded in meeting their primary endpoints, which should make BENLYSTA eligible for approval by the U.S. ...more	03 Nov 2009
Lupus Patients Who Receive Kidney Transplants Rarely Develop Lupus Nephritis Individuals with a history of lupus who receive a kidney transplant rarely develop the serious inflammatory condition lupus nephritis in their new organ, according to a paper being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA. The findings indicate that having lupus should not keep individuals from seeking a kidney transplant if they need one. ...more	02 Nov 2009
Cellular Mechanism That Causes Lupuslike Symptoms In Mice Identified By Stanford Study Macrophages, the scavenger cells of the body's immune system, are responsible for disposing of dying cells. Stanford University School of Medicine researchers have identified one pathway in this important process in mice that, if disrupted, causes a lupuslike autoimmune disease. The findings could lead to both a better understanding of the cause of lupus in humans and potential drug treatments for the disorder, which affects an estimated 1.5-2 million people in the United States. ...more	19 Oct 2009
Lupus Patients Perceive Benefit From Cardiovascular Disease Prevention Counseling Program According to a new study by Hospital for Special Surgery investigators presented at the American College of Rheumatology meeting on October 21 in Philadelphia, most lupus patients are not aware that their condition puts them at a higher risk for cardiovascular disease and a counseling program is a valuable way to promote education and lifestyle change. ...more	19 Oct 2009
The Lupus Foundation Of America Urges Key Stakeholders To Implement Report Recommendations The Lewin Group, a national health care consulting firm, issued recommendations on ways to overcome the barriers that have obstructed lupus drug development resulting in no new drug approval for this disease in more than 50 years- since the Eisenhower Administration. The recommendations are included in the report Overcoming Barriers to Drug Development in Lupus, which is the outcome of a 9-month study commissioned by the Lupus Foundation of America, Inc. (LFA). ...more	07 Oct 2009
National Report Shines Light On Lupus 50-Year Treatment Drought The Lewin Group, a national health care consulting firm, has issued recommendations on ways to overcome the barriers that have obstructed lupus drug development resulting in no new drug approval for this disease in more than 50 years - since the Eisenhower Administration. The recommendations are included in the report, "Overcoming Barriers to Drug Development in Lupus," which is the outcome of a 9-month study commissioned by the Lupus Foundation of America, Inc. (LFA). ...more	07 Oct 2009
Young Women With Autoimmune Condition Need To Be Warned About The Dangers Of Smoking And Use Of Oral Contraceptives An article published Online First and in the November edition of The Lancet Neurology reports that women with a particular subtype of antibody called lupus anticoagulant (LA) have a more than 40-fold increased risk of stroke. Moreover, they have a 5-fold increased risk of heart attack compared with the general population of young women. The autoimmune condition antiphospholipid syndrome mostly affects young women. ...more	28 Sept 2009
The Lupus Foundation Of America, Inc. Asks Supporters To Band Together For Lupus It's been 50 years since the U.S. Food and Drug Administration (FDA) approved a medication to treat lupus -- when Dwight D. Eisenhower was President! To highlight the need for safer, more tolerable, and effective medications, the Lupus Foundation of America, Inc. (LFA) today launched its new campaign, Band Together for LupusSM, which encourages people to wear an LFA purple wristband until there is a medication approved specifically for lupus by the FDA. ...more	23 Sept 2009
Race Shown To Affect Severity Of Lupus Disease In patients with systemic lupus erythematosus, their race can affect how severe the disease will become, according to a new study. Systemic lupus erythematosus (SLE) is the most common form of lupus a chronic inflammatory disease that can affect various parts of the body, especially the kidneys, joints, blood and nervous system. ...more	09 Sept 2009
Novel Evidence-Based SLE Responder Index Described In Peer Reviewed Publication As Potentially Significant Advance In Lupus Drug Development Human Genome Sciences, Inc. (NASDAQ:HGSI) announced publication by the journal of an article describing the development and use of a novel evidence-based systemic lupus erythematosus (SLE) Responder Index selected as the primary endpoint of two pivotal Phase 3 clinical trials of BENLYSTA™ (belimumab) in serologically active patients with SLE. ...more	07 Sept 2009
Shortage Of Lupus Patients Challenges Growing Number Of Clinical Studies It has been more than 50 years since the U.S. Food and Drug Administration (FDA) last approved a new medicine specifically for lupus - when Dwight D. Eisenhower was president. Existing treatments have been "borrowed" from other disorders and the risk/benefit ratio of these treatments is far from optimal. However, hope is on the horizon. ...more	03 Sept 2009
UCB And Immunomedics Announce Positive Results For Epratuzumab Phase IIb Study In Systemic Lupus Erythematosus (SLE) UCB and Immunomedics (NASDAQ: IMMU) announced top-line results from UCB's Phase IIb clinical study comparing epratuzumab to placebo in patients with systemic lupus erythematosus (SLE, also commonly known as lupus). The data from the 12-week dose and regimen-ranging study demonstrated clinical meaningful treatment effect of epratuzumab over placebo in SLE patients. The 227 patients in this study had moderately (30%) to severely (70%) active disease in multiple organ systems. ...more	28 Aug 2009
Immune Responses To Flu Vaccine Are Diminished In Lupus Patients Patients with the autoimmune disease systemic lupus erythematosus (SLE) have an increased risk of infection, due to both disturbances in their immune responses and treatment with immunosuppressive drugs. Because morbidity and mortality related to influenza are increased in immunocompromised patients, it is recommended that patients with SLE get annual flu shots, which are safe and do not increase disease activity. ...more	31 July 2009
Human Genome Sciences And GlaxoSmithKline Announce Positive Phase 3 Study Results For BENLYSTA(TM) In Systemic Lupus Erythematosus Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) announced that BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). ...more	21 July 2009
Lupus Research Institute Highly Encouraged By Benlysta(TM) Trial Results The Lupus Research Institute (LRI) and its National Coalition of state and local organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline on the highly promising results of this landmark clinical trial of Benlysta(TM) (belimumab) for people with systemic lupus. "We are very hopeful that we now are strongly on our way to the first new treatment for lupus in 50 years," said LRI President, Margaret G. Dowd. ...more	21 July 2009
Pages of Results: 1 2 3 4 5 6 7 8 9 10 11 12 13 [Next] [Last Page]
Lupus News courtesy of Medical News Today	back to top

Medical News

Looking for a Job?

Career Center

Popular Tools

Disclaimer Contact Us Privacy Policy Website Search	We comply with the HONcode standard for health trustworthy information: Verify here. Copyright © 2007 GlobalRPh Inc.